Sona Nanotech files patent application for photothermal light device

Sona Nanotech (CSE:SONA) submits a patent application to the U.S. Patent and Trademark Office for its proprietary photothermal light device.

FendX and McMaster University partner on spray nanotechnology

FendX Technologies (CSE:FNDX) reveals a partnership with McMaster University to advance the development of a spray nanotechnology.
Negotiating in a meeting room

NDatalyze to acquire Mindbalanced

NDatalyze (CSE:NDAT) has announced it has entered into an arms-length agreement to acquire a 100 per cent interest of Mindbalanced.

Canadian biotech company reports positive autism treatment results

Marvel Biosciences (TSXV:MRVL) reports promising interim results on its lead drug candidate, MB-204, as a new treatment for autism.

Why carbon-based imaging drug advancement is the future of life sciences  

The Canadian life sciences sector is one of the fastest growing industries in Canada as it seeks to make innovative products.

FSD Pharma submits clinical trial application for Unbuzzd drink

FSD Pharma (CSE:HUGE) has submitted a clinical trial application to assess its Unbuzzd beverage in a planned Phase 1b clinical trial.

Novo Nordisk stock hits new high on next-gen weight-loss drug results

Novo Nordisk (NYSE:NVO) stock jumped to a record high after it updated investors on positive results from a trial of a new weight loss…

Buzz on the Bullboards: Who is shining through the market slump?

The market story this week has been less impressive on both sides of the border than what we saw in the week where February…

Bausch Health subsidiary reveals Phase 2 study of Relistor

Bausch Health Companies has revealed that its subsidiary Salix Pharmaceuticals is initiating a Phase 2 study of its drug candidate Relistor

Oncolytics Biotech to initiate new pancreatic cancer therapy study

Oncolytics Biotech (TSX:ONC) initiated a new Phase 1/2 cohort to evaluate a novel treatment approach to pancreatic cancer.

BioNxt completes study on its oral MS treatment

BioNxt (CSE:BNXT) completed its comparative pharmacokinetic study for its oral dissolvable film to treat multiple sclerosis.

MedX Health shares rise on skin cancer pilot project

Shares of MedX Health (TSXV:MDX) received a boost Wednesday morning after the release of skin cancer pilot project results.
weight loss pills and bottles with stomach circumference measurements

Viking Therapeutics’ new weight-loss drug shows early potential

Viking Therapeutics, a clinical-stage biopharmaceutical stock, is sharing positive top-line data from its phase-2 clinical trial of VK2735.

Reliq Health Technologies expands mental health offering

Reliq Health Technologies (TSXV:RHT) will now provide cognitive assessments as part of its mental health services to improve early detection.

Contrarian play Datametrex AI sets sights on shareholder value

Recent news flow from Datametrex AI (TSXV:DM) suggests the company is on the path to profitable growth and shareholder value generation.
MindBio Therapeutics chief executive officer Justin Hanka.

Psychedelic stock clears hurdle to treating depression with LSD

Psychedelic stock MindBio (CSE:MBIO) is revealing positive top-line data from its pioneering microdosing clinical trial to treat depression.

Clearmind Medicine to begin alcohol use disorder clinical trial

Clearmind Medicine (CSE:CMND) has received approval to begin its phase I/IIa clinical trial for alcohol use disorder in Israel.

An investor’s gateway into the cancer immunotherapy market is with this Canadian biotechnology company 

The overarching cancer immunotherapy market continues growing at unprecedented rates, and BioVaxys Technology is ready to capitalize on it.
WELL Health - Hamed Shahbazi, Founder and CEO (third from right).

WELL Health streamlining business towards profitable growth

WELL Health (TSX:WELL) has made an integration update to streamline its business operations and position itself for profitable growth.

Buzz on the Bullboards: Where volatility meets opportunity

Some indices hit lows not seen in nearly a year after a concerning inflation report, only to bounce back the next day.